Viscardi Rose M, Kaplan Jennifer, Lovchik Judith C, He Ju Ren, Hester Lisa, Rao Srinivas, Hasday Jeffrey D
Department of Pediatrics, University of Maryland School of Medicine, University of Maryland at Baltimore, Baltimore, Maryland, USA.
Infect Immun. 2002 Oct;70(10):5721-9. doi: 10.1128/IAI.70.10.5721-5729.2002.
Ureaplasma urealyticum respiratory tract colonization in preterm infants has been associated with a high incidence of pneumonia and the development of bronchopulmonary dysplasia. However, study of this human pathogen has been hampered by the absence of animal models. We have developed the first juvenile mouse model of Ureaplasma pneumonia and characterized the histopathology during the month following inoculation. C3H/HeN mice were inoculated intratracheally with a mouse-adapted clinical Ureaplasma isolate (biovar 2) or sham inoculated with 10B broth. Culture of lung homogenates and PCR of DNA from bronchoalveolar lavage fluid (BAL) confirmed the presence of Ureaplasma in 100% of inoculated animals at 1 day, 60% at 2 days, 50% at 3 days, and 25% at 7 and 14 days. Ureaplasma was undetectable 28 days postinoculation. There were marked changes in BAL and interstitial-cell composition with increased number of polymorphonuclear leukocytes 1 to 2 days and 14 days postinoculation and macrophages at 2 and 14 days postinoculation. The Ureaplasma infection caused a persistent focal loss of airway ciliated epithelium and a mild increase in interstitial cellularity. There were no differences in BAL protein concentration during the first 28 days, suggesting that pulmonary vascular endothelial barrier integrity remained intact. Comparison of BAL cytokine and chemokine concentrations revealed low levels of tumor necrosis factor alpha (TNF-alpha) at 3 days and monocyte chemoattractant protein 1 at 7 days in Ureaplasma-infected mice but a trend toward increased TNF-alpha at 14 days and increased granulocyte-macrophage colony-stimulating factor and interleukin-10 at 28 days. These data suggest that Ureaplasma alone may cause limited inflammation and minimal tissue injury in the early phase of infection but may promote a mild chronic inflammatory response in the later phase of infection (days 14 to 28), similar to the process that occurs in human newborns.
解脲脲原体在早产儿呼吸道定植与肺炎高发及支气管肺发育不良的发生有关。然而,由于缺乏动物模型,对这种人类病原体的研究受到了阻碍。我们建立了首个解脲脲原体肺炎幼鼠模型,并对接种后一个月内的组织病理学特征进行了描述。将适应小鼠的临床解脲脲原体分离株(生物变种2)经气管内接种到C3H/HeN小鼠体内,或用10B肉汤进行假接种。肺匀浆培养和支气管肺泡灌洗液(BAL)DNA的PCR检测证实,接种后1天,100%的接种动物体内存在解脲脲原体;2天为60%;3天为50%;7天和14天为25%。接种后28天未检测到解脲脲原体。BAL和间质细胞组成有明显变化,接种后1至2天和14天多形核白细胞数量增加,接种后2天和14天巨噬细胞数量增加。解脲脲原体感染导致气道纤毛上皮持续局灶性缺失,间质细胞轻度增多。前28天BAL蛋白浓度无差异,提示肺血管内皮屏障完整性保持完好。对BAL细胞因子和趋化因子浓度的比较显示,解脲脲原体感染小鼠在3天时肿瘤坏死因子α(TNF-α)水平较低,7天时单核细胞趋化蛋白1水平较低,但在14天时TNF-α有升高趋势,28天时粒细胞-巨噬细胞集落刺激因子和白细胞介素-10升高。这些数据表明,单独的解脲脲原体在感染早期可能引起有限的炎症和最小的组织损伤,但在感染后期(第14至28天)可能促进轻度慢性炎症反应,类似于人类新生儿发生的过程。